Ranitidine and Injection site hypersensitivity - a phase IV clinical study of FDA data

Summary:

Injection site hypersensitivity is reported as a side effect among people who take Ranitidine (ranitidine), especially for people who are female, 50-59 old, also take Sertraline, and have Uterine fibroids.

The phase IV clinical study analyzes which people have Injection site hypersensitivity when taking Ranitidine. It is created by eHealthMe based on reports of 233,168 people who have side effects when taking Ranitidine from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Injection site hypersensitivity?

Injection site hypersensitivity is found to be associated with 200 drugs and 229 conditions by eHealthMe. Check the latest studies of Injection site hypersensitivity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

233,168 people reported to have side effects when taking Ranitidine.
Among them, 24 people (0.01%) have Injection site hypersensitivity.

Could Ranitidine cause Injection site hypersensitivity?

Among these 24 people:

What is the gender of people who have Injection site hypersensitivity when taking Ranitidine? *

female: 95.83 %
male: 4.17 %

What is the age of people who have Injection site hypersensitivity when taking Ranitidine? *

What are other drugs people take besides Ranitidine? *

What are other side effects people have besides Injection site hypersensitivity? *

Itching: 20 people, 83.33%
Injection Site Pruritus (severe itching at injection site): 20 people, 83.33%
Visual Impairment: 19 people, 79.17%
Pain In Extremity: 19 people, 79.17%
Injection Site Warmth: 19 people, 79.17%
Injection Site Bruising: 19 people, 79.17%
Fever: 19 people, 79.17%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 18 people, 75.00%
Food Aversion (we reject certain foods for a reason): 18 people, 75.00%
Food Intolerance (inability to have food): 18 people, 75.00%

What are the existing conditions these people have? *

Uterine Fibroids (benign growths of the muscle inside the uterus): 18 people, 75.00%
Drowsiness: 15 people, 62.50%
Neuroendocrine Tumor: 4 people, 16.67%
Insomnia (sleeplessness): 3 people, 12.50%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 8.33%
Drug Dependence: 2 people, 8.33%
Pain: 1 person, 4.17%
Osteoporosis (bones weak and more likely to break): 1 person, 4.17%
Osteopenia (a condition where bone mineral density is lower than normal): 1 person, 4.17%
Neuropathy Peripheral (surface nerve damage): 1 person, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and have Injection site hypersensitivity?

- Check whether Injection site hypersensitivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ranitidine:

Ranitidine (234,475 reports)

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site hypersensitivity:

Injection site hypersensitivity (200 drugs)

Browse all the conditions that are associated with Injection site hypersensitivity:

Injection site hypersensitivity (229 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine (the active ingredients of Ranitidine) and Ranitidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.